Suzlon Wins ATD's BEST Award 2025 for Empowering India's Next-Generation Green Energy Leaders
About ATD
The Association for Talent Development (ATD) is the world's largest professional membership organization supporting those who develop the knowledge and skills of employees, improve performance, and help to achieve results for the organizations they serve. Established in 1943, the association was known as the American Society for Training & Development (ASTD).
ATD's members come from more than 100 countries and work in public and private organizations in every industry sector. ATD supports talent development professionals who gather locally in volunteer-led US chapters, international member networks, and with international strategic partners. For more information, visit www.td.org.
About The Suzlon Group
The Suzlon Group is a leading global renewable energy solutions provider, with approximately 21.1 GW* of wind energy capacity installed across 17 countries. Headquartered at Suzlon One Earth in Pune, India, the Group includes Suzlon Energy Limited (NSE: SUZLON, BSE: 532667) and its subsidiaries. A vertically integrated organisation, Suzlon has in-house R&D centres in Germany, the Netherlands, Denmark, and India, and world-class manufacturing facilities across India.
With 30 years of operational excellence and a diverse workforce of ~7,800 employees, Suzlon is India's No. 1 Renewable Energy Solutions company, managing 15.1 GW of assets and an additional ~6 GW installed outside India. Its portfolio includes the advanced 2.x MW and 3.x MW series of wind turbines.
*Global installations of Suzlon-manufactured wind turbine generators. Data as of 31st March 2025
Suzlon corporate website: www.suzlon.com.
Follow us on Social media:FacebookTwitterLinkedIn
Instagram Click here for Media Contact Details
Submit your press release
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
HGS appoints Venkatesh Korla as Global CEO
AUSTIN, Texas, June 11, 2025 /PRNewswire/ -- Hinduja Global Solutions (HGS) (listed on BSE & NSE), a leading provider of digital experience, business process management (BPM), and digital media services, has announced the appointment of Mr. Venkatesh Korla as the new Global CEO of HGS. The HGS Board approved the elevation of Venkatesh, formerly President & CEO of HGS Americas, to the role of Global CEO, effective May 28, 2025. He succeeds Mr. Partha DeSarkar, who has been at the helm of the company since 2006 and is expected to retire in September 2025. Venkatesh is an accomplished business leader with 25+ years of experience in core digital services and tech-enabled customer experience (CX). He has an impressive track record of growing high-performance teams globally and fostering lasting client relationships. In his earlier stints, he has been part of organizations providing expert consultation on digital strategies and solutions to Global 1000 companies, healthcare institutions, universities, and not-for-profit organizations. He also founded Element Solutions, later acquired by HGS and now forms the foundation of HGS' tech services business, that delivers strategic consulting, data analytics, marketing technology, intelligent automation, and cloud solutions to clients across the private and public sectors. Mr. Ashok P. Hinduja, Chairman, HGS said, "The company is currently evolving to align towards an AI-led future in line with the technology changes in the market and evolving client needs. Venkatesh, with his deep expertise and proven track record of leading digital transformation at scale, is the right person to lead HGS' future growth with a digital approach. On behalf of the Board, I would like to congratulate him and am looking forward to collaborating on the new journey ahead." Speaking on his elevation as the new Global CEO, Venkatesh Korla said, "It is a tremendous honor to take on the role of Global CEO at HGS. I step into this position with deep respect for the legacy we've built so far, led by the strong leadership of Partha DeSarkar, and a sense of great excitement for how we can shape the future. Our people are our greatest strength, and by combining their passion with the power of technology, we will create meaningful, human-centered solutions that redefine how we serve our clients and their customers, and accelerate our journey as a digitally-led organization." Photo - - View original content to download multimedia: SOURCE Hinduja Global Solutions Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
7 hours ago
- Business Upturn
NSE gets SEBI nod to launch monthly electricity futures, aims to deepen power market reforms
By News Desk Published on June 11, 2025, 19:21 IST The National Stock Exchange of India (NSE) has received regulatory approval from the Securities and Exchange Board of India (SEBI) to launch monthly electricity futures contracts, marking a significant milestone in India's efforts to deepen its power markets and drive long-term structural reforms under the Electricity Act, 2003. The new futures contracts will provide market participants with tools to hedge against electricity price volatility, offer more accurate price signals, and encourage capital investment across the electricity value chain, including generation, transmission, distribution, and retail. According to Niti Aayog, India's transition to net-zero emissions by 2070 will require over $250 billion in annual investment until 2047, with more than 50% of installed power capacity expected to come from solar and wind by 2030. A liquid electricity derivatives market is seen as critical for attracting large-scale domestic and international climate finance. NSE MD & CEO Ashishkumar Chauhan stated that the approval is 'only the beginning' of the exchange's broader electricity derivatives strategy. Future offerings could include contracts for difference (CFDs) and longer-duration contracts like quarterly and annual futures, subject to regulatory clearances. The contracts will be financially settled and cleared by NSE Clearing Limited, a SEBI-recognized Qualified Central Counterparty (QCCP) with a robust settlement mechanism and strong capital base. NSE was the first Indian exchange to enter the electricity space, having established Power Exchange India Limited (PXIL) in 2008. With its combined expertise in spot and derivatives markets, NSE aims to build a comprehensive and liquid electricity derivatives ecosystem, aligned with key policy initiatives like Market-Based Economic Dispatch (MBED) and market coupling by CERC. This development strengthens NSE's position as a global leader in derivatives, having been ranked the world's largest derivatives exchange by trading volume in 2024 by the Futures Industry Association (FIA). News desk at
Yahoo
10 hours ago
- Yahoo
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral ischemic stroke WILLOWBROOK, Ill., June 11, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited (Reuters: Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies), one of the world's leading pharmaceutical companies. This strategic investment brings Sun Pharma's total commitment in Pharmazz to $40 million (including a previous $15 million equity investment). 'We believe sovateltide has the potential to redefine the treatment of ischemic stroke, which has not seen a new FDA approved non-thrombolytic therapy in over 30 years. This investment means we are now fully funded to complete our pivotal Phase 3 study and execute on our mission to make this first in class therapy available to stroke patients,' said Emeritus Prof. Anil Gulati, CEO and Founder of Pharmazz. 'We deeply value Sun Pharma's continued partnership, which strengthens our ability to bring our therapies to patients worldwide.' The new funding will provide Pharmazz with the capital required to complete the pivotal U.S. Phase 3 clinical trial of sovateltide (known as Tycamzzi® and Tyvalzi™ in international markets), its lead drug candidate for treating acute cerebral ischemic stroke. Dr. Neil Marwah, President of Pharmazz, added, 'This investment gives us the operational runway to execute a complex, multi-country clinical trial and scale the company responsibly as we prepare for a potential public offering. We are thrilled to strengthen our partnership with Sun Pharma, whose continued support reflects deep confidence in our platform and our ability to execute.' Phase 3 Trial of Sovateltide for Stroke Covered by Special Protocol Assessment Sovateltide is a first-in-class endothelin-B receptor agonist to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke patients. Pharmazz is initiating the Phase 3 RESPECT-ETB ( ID: NCT05691244) trial at 65 sites in the US, Germany, Spain, and the UK, designed to enroll 514 stroke patients. The primary endpoint is the proportion of patients demonstrating functional independence post-stroke, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after stroke onset. Commercially Approved in India: Early Validation from 60,000+ patients Sovateltide was approved in 2023 in India and marketed by Sun Pharma under the brand name Tyvalzi™, offering compelling proof of concept for global commercialization. In a randomized, placebo-controlled, multicenter clinical trial conducted in 158 cerebral ischemic stroke patients conducted in India, the product was shown to be well tolerated and effective in improving neurological outcomes when administered within 24 hours of stroke symptoms. Patients on Sovateltide were 22.7% more likely to achieve functional independence at 90 days (as measured by mRS score 0–2; p=0.0045) Sovateltide delivered a 17.1% higher rate of favorable National Institutes of Health Stroke Scale (NIHSS) scores (p=0.0024) The ordinal shift in mRS and NIHSS score between control and sovateltide groups was favorable towards sovateltide across the entire range. Results represent the first statistically significant clinical data in stroke in 30 years, since the introduction of alteplase (tPA) Over 60,000 patients treated to date since commercial launch in India Targeting a Multibillion-Dollar Market with a Broader Therapeutic Window Stroke remains one of the leading causes of disability and death globally, with over 7 million ischemic strokes annually. Today, fewer than 15% of patients receive approved interventions, largely due to their narrow treatment window and strict eligibility criteria. Sovateltide's 24-hour dosing window and broader eligibility could expand access—particularly for underserved populations—and position it as a major advance in acute stroke care. If successful in Phase 3 and subsequently approved, sovateltide has strong commercial potential and is expected to be a foundational product in the Pharmazz emerging neurology franchise. About Sovateltide Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide is unique because its action site is the neural progenitor cells. Sovateltide promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz, Inc. obtained marketing authorization for two of its first-in-class drug molecules, centhaquine and sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. In addition, the US Food and Drug Administration (FDA) has approved two phase III INDs for centhaquine as an agent for hypovolemic shock and sovateltide for cerebral ischemic stroke. Additional information may be found on the Company's website, About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. and global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit Disclaimer: Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors Kabir Marwah MediaShruti Gulati Tel +1 630 780 6087 Tel +1 630 780 6087 E mail E mail produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
